Impact of oat-based products on human gastrointestinal tract

Publisher Copyright: © by Aiga Staka 2015.Oat is rich in valuable nutrients. In comparison to other cereals, oat contains more total proteins, carbohydrate, fat, non-starch fibre, as well as unique antioxidants (one of them - avenanthramides), vitamins, and minerals. One of the most often studied components of oats is β-glucan - a type of soluble dietary fibre located throughout the starch endosperm, but with highest concentration in the bran. Many studies have shown the beneficial health effects of oat β-glucan as a soluble dietary fibre. Until now, most of the studies on this nutrient have been conducted in the cardiovascular and diabetology field. This article aimed to review the literature on studies that investigated the effects of oat-based products on human gastrointestinal tract - gastrointestinal microflora, irritable bowel syndrome, inflammatory bowel disease as well as prevention/treatment of colorectal cancer. A literature search was conducted using PubMed database. More than 80 potential articles were identified, which were selected afterwards according to aims of our study. Studies done on human were preferred. A long-term dietary intake of oat-based products improves human intestinal microflora, could have benefits in irritable bowel syndrome, and probable effects were seen in patients with ulcerative colitis, but this remains to be proven. There are few studies regarding prevention/treatment of colorectal cancer and they do not show clear benefit nor provide recommendations.publishersversionPeer reviewe

Role of body bioelectrical impedance analysis in the assessment of the nutritional status of patients with inflammatory bowel disease and metabolic syndrome

Nutrition has an important role in the management of inflammatory bowel disease (IBD) and metabolic syndrome (MS). The goal of this study was to assess the nutritive status of patients treated with IBD and metabolic syndrome in the Gastroenterology Centre, Pauls Stradinš Clinical University Hospital. Body bioelectrical impedance analysis (BIA) using GENIUS 220 PLUS (Jawon Medical) was used to determine Body Mass Index (BMI) kg/m2, Metabolic Body Fat (MBF) kg, Soft Lean Mass (SLM) kg, Total Body Water (TBW) kg, body composition, metabolic type, Basal Metabolic Rate (BMR) kcal, and total Energy Expenditure (TEE) kcal in patients with BD and metabolic syndrome and in a similarly aged control group. The obtained data showed that BMI was not correlated with MBF, BTW and Lean Body Mass (LBM). Patients with Crohn's disease (CD) had normal value of BMI (M 24.3 kg/m2; F 20.2kg/m2), but we found variety-specific differences in body composition that confirmed deficiency or increase of specific bodyparameters. The performed prospective study confirmed the importance of the more precise nutritional status analysis, as it was clinically useful for the nutritional management of IBD. Patients with CD had expressed nutrient deficiency, sarcopenia, and reduced amount of proteins and minerals. For patients with MS, sarcopenia was present despite obesity.Peer reviewe

McKittrick-Wheelock Syndrome: A Case Report

publishersversionPeer reviewe

Kalcija antagonistu - foridona, verapamila un nifedipina ietekme uz sirds funkcionalo stavokli hipertoniskas slimibas slimniekiem

Available from Latvian Academic Library / LAL - Latvian Academic LibrarySIGLELVLatvi

Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease : Case report and review of the literature

Secondary systemic (AA) amyloidosis is reported as a serious complication that occurs in long-standing Crohn's disease (CD), with an incidence of 0.3-10.9%. Various therapeutic approaches using medicines and elemental diet have been recomended, but still there are no established standards of treatment for secondary systemic amyloidosis in CD. Only a few studies have shown the role of TNFα ihibitors in the treatment of AA amyloidosis over a long term period. We report the case of a 24-year-old male with CD complicated by AA amyloidosis with renal and gastrointestinal tract involvement treated with infliximab as induction therapy. Intestinal AA amyloidosis progression occurred at the same time with the development of CD as an early complication, whereas duration of CD prior to the diagnosis of renal AA amyloidosis was 6 years. Infliximab therapy (3 infusions) caused a significant decrease of serum amyloid A protein (by 97.9%), C-reactive protein (by 70%), improvement of disease activity index, and CD caused clinical symptoms. At the same time gradual progression of the renal damage (reduction of renal function) was not affected by the treatment. Direct efficacy of infliximab infusions on serum amyloid protein level may support the hypothesis of TNFα induced reduction on the progression of AA amyloidosis described in previous study reports. Targeted histological analysis of tissue biopsy is crucial to clarify the presence of AA amyloidosis in CD induced multiorgan damage cases.publishersversionPeer reviewe